Form 4: HeartBeam President Granted 55,172 Stock Options

HeartBeam, Inc. President Robert Paul Eno was granted 55,172 stock options with an exercise price of $1.45, vesting in two tranches in 2026.

Summary

• Robert Paul Eno, President of HeartBeam, Inc. (BEAT), was granted 55,172 derivative securities in the form of stock options.
• The options have an exercise price of $1.45 per share.
• The grant date for these 'Special Options' was February 9, 2026.
• One half of the total options will vest on March 31, 2026, which is the three-month anniversary of the January 1, 2026 vesting commencement date.
• The remaining half of the options will vest on June 30, 2026, the six-month anniversary of the vesting commencement date.
• These options were issued from the Company's 2022 Equity Incentive Plan and expire on January 1, 2036.
• Following this transaction, Robert Paul Eno beneficially owns 55,172 derivative securities directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it aligns the President's long-term incentives with shareholder value through equity ownership, which is generally favorable for corporate governance and performance motivation.

Positives

• The grant of stock options aligns the President's long-term financial interests with those of the shareholders, incentivizing performance and value creation.
• The options are issued under an existing equity incentive plan, indicating a structured approach to executive compensation.

Negatives

• No immediate negatives are apparent from this routine insider transaction.

Risks

• Potential future dilution for existing shareholders if the options are exercised, increasing the number of outstanding shares.
• The value of the options is subject to the future market price of HeartBeam's common stock, which carries inherent market risk.

Future Outlook

The grant of long-term equity incentives suggests a focus on retaining key management and motivating them towards achieving future company milestones and increasing shareholder value over the vesting period.

Industry Context

StockSavvy.ai notes that granting stock options is a common practice in the medical device and biotech industry to incentivize executives and align their interests with long-term company performance, especially for growth-oriented companies like HeartBeam that rely on innovation and strategic execution.

Comparison to Industry Standards

• StockSavvy.ai observes that equity grants to executives are standard practice across the healthcare technology sector, comparable to compensation structures at companies like iRhythm Technologies (IRTC) or AliveCor, aiming to retain talent and motivate performance.
• The specific grant size of 55,172 options and the two-tranche vesting schedule over six months are typical for executive-level incentives, designed to provide both immediate motivation and long-term retention.

Corporate Governance

Related Party Transactions

• Grant of 55,172 stock options to Robert Paul Eno, the company's President, under the 2022 Equity Incentive Plan, which constitutes a transaction with a related party.

Stakeholder Impact

• Shareholders: Potential for increased management motivation and alignment with long-term company performance, balanced against potential future dilution if options are exercised.
• Management: Enhanced long-term incentive and direct financial interest in the company's stock performance.

Next Steps

• Vesting of the first half of the options on March 31, 2026.
• Vesting of the remaining half of the options on June 30, 2026.

Key Dates

Recommendation

The grant of stock options to the President is a routine executive compensation event that aligns management's interests with long-term shareholder value. It does not present new fundamental information to warrant a change in investment thesis, thus a 'hold' recommendation is appropriate for existing investors.

Keywords

HeartBeam, BEAT, stock options, equity incentive plan, executive compensation, Form 4, insider transaction, Robert Paul Eno, vesting